- Home
- HCI vs KARD Comparison
HCI vs KARD Comparison
Compare HCI & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HCI | KARD |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2008 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HCI | KARD |
|---|---|---|
| Price | $174.69 | $14.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $230.00 | N/A |
| AVG Volume (30 Days) | 104.2K | ★ 508.2K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 155.57 | N/A |
| EPS | ★ 11.05 | N/A |
| Revenue | ★ $900,946,000.00 | N/A |
| Revenue This Year | $11.44 | N/A |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $15.87 | ★ N/A |
| Revenue Growth | ★ 20.12 | N/A |
| 52 Week Low | $144.75 | $13.75 |
| 52 Week High | $210.50 | $27.00 |
Technical Indicators
Market Signals| Indicator | HCI | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 36.27 | 30.37 |
| Support Level | $172.50 | N/A |
| Resistance Level | $182.10 | $22.81 |
| Average True Range (ATR) | 4.01 | 1.45 |
| MACD | -1.50 | -0.35 |
| Stochastic Oscillator | 19.41 | 13.09 |
Price Performance
Historical ComparisonAbout HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.